Abstract W P224: Higher Pre-Hospital Blood Pressure Prolongs Door to Needle Thrombolysis Times

Stroke ◽  
2015 ◽  
Vol 46 (suppl_1) ◽  
Author(s):  
Digvijaya Navalkele ◽  
Chunyan Cai ◽  
Mohammad Rahbar ◽  
Renganayaki Pandurengan ◽  
Tzu-Ching Wu ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Small Sample Size ◽  
Heart Association ◽  
Small Sample ◽  
Categorical Variables ◽  
Continuous Variables ◽  
Intravenous Tissue Plasminogen Activator ◽  
Number Of Patients

Background: Per American Heart Association guidelines, blood pressure (BP) should be < 185/110 to be eligible for intravenous tissue plasminogen activator (tPA). It is shown that door to needle (DTN) time is prolonged in patients who require anti-hypertensive medications prior to thrombolysis in the emergency department (ED). To our knowledge, no studies have focused on pre-hospital BP and its impact on DTN times. We hypothesize that DTN times are longer for patients with higher pre-hospital BP. Methods: We conducted a retrospective review of acute ischemic stroke patients who presented between 1/2010 and 12/2010 to our ED through Emergency Medical Services (EMS) within 3-hrs of symptom onset. Patients were identified from our registry and categorized into two groups: Pre-hospital BP ≥ 185/110 (Pre-hsp HBP) and < 185/110 (Pre-hsp LBP). BP records were abstracted from EMS sheets. Two groups were compared using two-sample t-test or Wilcoxon rank sum test for continuous variables and Chi-square test or Fisher’s exact test for categorical variables. Results: A total of 107 consecutive patients were identified. Out of these, 75 patients (70%) were treated with tPA. Among the patients who received thrombolysis, 35% had pre-hospital BP ≥ 185/110 (n= 26/75). Greater number of patients required anti-hypertensive medications in ED in high BP group compared to low BP group (Pre-hsp HBP n= 14/26, 54%; Pre-hsp LBP n= 13/49, 27%, p < 0.02). Mean door to needle times were significantly higher in Pre-hsp HBP group. (mean ± SD 87.5± 34.2 Vs. 59.7±18.3, p<0.0001). Analysis of patients only within the Pre-hsp HBP group (n= 26) revealed that DTN times were shorter if patients received pre-hsp BP medications compared to patients in the same group who did not receive pre-hsp BP medication (n= 10 vs 16; mean ± SD 76.5 ± 25.7 Vs. 94.3 ± 37.7, p = 0.20) Conclusion: Higher pre-hospital BP is associated with prolonged DTN times and it stays prolonged if pre-hospital high BP remains untreated. Although the later finding was not statistical significant due to small sample size, pre-hospital blood pressure control could be a potential area for improvement to reduce door to needle times in acute ischemic stroke.

scholarly journals Emergency Department Adherence to American Heart Association Guidelines for Blood Pressure Management in Acute Ischemic Stroke

Stroke ◽  
2012 ◽  
Vol 43 (2) ◽  
pp. 557-559 ◽  
Author(s):  
Erin McDonough Grise ◽  
Opeolu Adeoye ◽  
Christopher Lindsell ◽  
Kathleen Alwell ◽  
Charles Moomaw ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Emergency Department ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
American Heart Association ◽  
American Heart ◽  
Heart Association ◽  
Pressure Management ◽  
Blood Pressure Management

Assessment of time from cytoreductive nephrectomy (CN) to initiation of targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC).

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 540-540
Author(s):  
Winston Vuong ◽  
Mark Chang ◽  
Nora Ruel ◽  
Joann Hsu ◽  
Courtney Carmichael ◽  
...  
Keyword(s):  
De Novo ◽  
Small Sample Size ◽  
Demographic Data ◽  
Small Sample ◽  
Categorical Variables ◽  
Continuous Variables ◽  
Cytoreductive Nephrectomy ◽  
Impaired Wound Healing ◽  
Estimated Blood Loss ◽  
Surgical Data

540 Background: For patients (pts) with de novo mRCC, the initiation of TT typically occurs at a window of 4-6 weeks following CN. Although this practice is thought to mitigate impaired wound healing, bleeding and other complications (cx) in the perioperative period potentially related to antiangiogenic TT, there is limited data to support this practice. Methods: An institutional database including over 670 pts with RCC was interrogated. Pts with de novo mRCC who had received CN and subsequent TT were identified. When available, demographic data, Charlson comorbidity index (CCI), body mass-index (BMI) and surgical data (estimated blood loss [EBL], intraoperative cx, etc.) were recorded. ICD-9 codes recorded up to 90 days following CN were evaluated; newly applied diagnoses with possible relationship to surgery were considered to be potential postoperative cx. For continuous variables, the Spearman correlation test was used to determine associations with time to TT. For categorical variables, Kaplan-Meier analyses were conducted to determine if time to TT varied across subgroups. Results: Of 270 pts with mRCC, 79 pts received cytoreductive nephrectomy. Of these, 36 pts received TT as an initial treatment strategy (others received IL-2, IFN or chemotherapy), and 30 pts had a documented date of TT initiation. Two pts were removed given receipt of preoperative TT, resulting in a total of 28 pts in the current analysis. Median time to TT was 46 days (range, 28-93). Median overall survival for the overall cohort was 17.2 months. No association was found between age, BMI, CCI, number of sites of metastasis and time to TT. Time to TT did not vary by race (Caucasian v other) or class of TT (VEGF-directed therapy v mTOR inhibitor). Furthermore, EBL and the frequency of intraoperative cx did not vary by time to TT. The most frequently encountered postoperative cx included pleural effusion, pain, fatigue and nausea. Conclusions: With the caveat of our small sample size, the lack of an association between operative cx and time to TT suggests that an abbreviated timeframe between CN and TT may be entertained. These findings warrant exploration in larger series and/or prospective validation.

Abstract TP69: Safety and Outcomes of IV Thrombolysis with Alteplase for Acute Ischemic Stroke Patients with Thrombocytopenia

Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
Haris Kamal ◽  
Nour Abdelhamid ◽  
Liang Zhu ◽  
Sean Savitz ◽  
James Grotta ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Strong Evidence ◽  
Demographic Data ◽  
Categorical Variables ◽  
Continuous Variables ◽  
Chi Square ◽  
Exact Test ◽  
Chi Square Test ◽  
Iv Tpa

Background: Intravenous tPA (IV tPA) has been the mainstay for reperfusion therapies for acute ischemic stroke (AIS) patients for 2 decades. Many contraindications from the initial NINDS trial were derived from experts’ consensus and not tested in the trial. Many AIS patients present with thrombocytopenia (< 100,000) and may be excluded from treatment in spite of lack of strong evidence. Some clinicians opt to treat these patients weighing the benefits and risks along with the lack of strong evidence behind this exclusion. We sought to evaluate the safety in AIS patients with low platelets receiving IV tPA as compared to those who do not. Methods: Restrospective chart review of all patients presenting with AIS between 1/2006 to 7/2016 at our center. We analyzed patients who had platelets <100,000 among this cohort and stratified them into those who were treated with IV tPA and those who received antiplatelet therapy only. Demographic data, medical history, medications, presence of sICH after treatment, presenting NIHSS were collected. Two sample Wilcoxon rank sum test was used to compare continuous variables between the two groups, and chi-square test or Fisher’s exact test used to compare categorical variables. Results: 21 patients were treated with IV tPA while 122 patients were treated with antiplatelets. Table 1 lists the demographic variables of the two groups with and without IV tPA. Patients included had moderate thrombocytopenia with very few <50,000. No significant differences were found in presenting NIHSS, race, gender, and history of atrial fibrillation between the two groups except platelets (p=0.0128), age (p=0.0462) and glucose (p=0.0279). Table 2 lists the outcome variables of mRS and symptomatic ICH. There was no petechial or sICH among 21 treated patients. Conclusion: While limited by small numbers and lack of randomization, our data suggest that IV tPA is safe in patients with moderately reduced platelet counts.

scholarly journals Mechanical thrombectomy in acute ischemic stroke: a single-center experience

2020 ◽  
Vol 8 (4S) ◽  
pp. 95-103
Author(s):  
K. M. Vakkosov ◽  
D. Yu. Naumov ◽  
N. I. Vodop`yanova ◽  
I. V. Moldavskaya ◽  
V. I. Ganyukov
Keyword(s):  
Ischemic Stroke ◽  
Carotid Artery ◽  
Acute Ischemic Stroke ◽  
Mechanical Thrombectomy ◽  
Small Sample Size ◽  
Small Sample ◽  
Stent Retriever ◽  
Federal State ◽  
First Pass Effect ◽  
First Pass

Aim. Mechanical thrombectomy is standard of care for the treatment of acute ischemic stroke. The objective of this study is to analyze the results of our own experience of endovascular treatment in Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases” Kemerovo.Methods. 12 patients with AIS and underwent mechanical thrombectomy with «Trevo» stent-retriever were included in this analysis. Primary outcomes included 90-day modified Rankin scale (mRS) score, first pass effect (FPE) and recanalization rate (TICI score), the combined incidence of postintervention hemorrhages and mortality at 90 days.Results. Among 12 patients (66.7% male, age 59.5 [57.5; 66.5] years) hypertension were in 100%, 61.5% had an ischemic heart disease, 53.8% was current smoking and atrial fibrillation. Median of the NIHSS scale was 13 points, mRS≥4 was in 75% of patients. In 33.3% was a tandem lesion (internal carotid artery terminus and middle cerebral artery) and 25% required stenting of the carotid artery. Good clinical outcomes (mRS≤2 at 90 days) were achieved in 77.8% (7/9) among surviving patients. The 90-day NIHSS score – 4 [1; 5]. The first pass effect and recanalization rate (TICI Scores 2b-3/3) was achieved in 50% and 91.7% of patients. The combined incidence of postintervention hemorrhages and mortality at 90 days was 33.3% and 25% respectively.Conclusion. Despite the small sample size, stent retriever mechanical thrombectomy in AIS provides satisfactory clinical results.

scholarly journals 225. Risk Factors for Mortality in Stenotrophomonas Bacteremia: A Retrospective Study

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S220-S220
Author(s):  
Glen Huang ◽  
Matthew R Davis ◽  
Paul R Allyn
Keyword(s):  
Los Angeles ◽  
Small Sample Size ◽  
Small Sample ◽  
Categorical Variables ◽  
Common Source ◽  
High Dose ◽  
Continuous Variables ◽  
Hospital System ◽  
Optimal Therapy ◽  
The Impact

Abstract Background Stenotrophomonas is a gram-negative organism typically associated with nosocomial infections. It is an emerging multi-drug resistant pathogen associated with significant morbidity and mortality in hospitalized patients. Optimal therapy is unknown. In this study, we evaluated the impact of treatment agent, dosing regimen, and patient characteristics on 30-day mortality for Stenotrophomonas bacteremia in our hospital system. Methods Retrospective chart review from April 2013 to September 2019 at Ronald Reagan and Santa Monica UCLA Medical Centers in Los Angeles, California. Adult patients who were hospitalized and received active therapy for Stenotrophomonas bacteremia were included in the study. Chi-square or Fischer test was used for categorical variables, Student’s t-test or Mann-Whitney U test was used for continuous variables. Results Sixty-nine patients were included in the study. The median age was 53 and 31 patients (44.9%) were female. Central line associated infections were the most common source of infection (79.7%, n = 55). Two patients (3%) had a relapse of infection. The overall 30-day mortality was 30.4% (n=21). The patients who did not survive to 30 days tended to have a higher Pitt bacteremia score, a longer length of stay, and were more likely to have used other antibiotics in the 30 days prior to culture collection. Trimethoprim-sulfamethoxazole (TMP-SMX) was the most common antibiotic used for treatment (n = 45, 65.2%). Of the patients who were treated with TMP-SMX, 19 were treated with high-dose (defined as 15 mg/kg or equivalent) and 26 had an alternative dosage after adjusting for renal function. There was no difference in 30-day mortality in the TMP-SMX high dose vs alternative dose (42.1% vs 30.8%, p = 0.53). Conclusion Stenotrophomonas bacteremia was associated with high mortality. High-dose TMP-SMX did not impact survival in our study; however, this may be due to small sample size. More research is needed to determine optimal therapy. Disclosures All Authors: No reported disclosures

Abstract WP23: Is There Increased Incidence of Subarachnoid Hemorrhage With Use of Stentrievers in Distal Circulation?

Stroke ◽  
2020 ◽  
Vol 51 (Suppl_1) ◽  
Author(s):  
Ashish Kulhari ◽  
Daniel Ro ◽  
Amrinder Singh ◽  
Farah Fourcand ◽  
Gurneel Kaur Dhanesar ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Subarachnoid Hemorrhage ◽  
Acute Ischemic Stroke ◽  
Small Sample Size ◽  
Small Sample ◽  
P Value ◽  
Anterior Circulation ◽  
Vessel Occlusion ◽  
Group A ◽  
Group B

Background: Multiple recent positive endovascular trials have proven mechanical thrombectomy as standard of care for large vessel occlusion (LVO) of the Anterior Circulation (AC). Post-thrombectomy subarachnoid hemorrhage (PT-SAH) is a known complication of this procedure. The aim of this study was to compare the incidence of SAH in proximal (ICA terminus and MCA M1) versus distal (MCA M2 and beyond) LVOs with use of stentrievers. Methods: Retrospective analysis of patients who underwent anterior circulation acute ischemic stroke interventions (AISI) at a community based, university affiliated comprehensive stroke center during a 5 year period (2014-2019) was done. AISI using stentrievers were separated in 2 groups based on location of LVO (Proximal and Distal). Post procedure CT heads were reviewed for SAH in location of stent deployment. Results: 2980 patients presented with acute ischemic stroke during the pre-specified time period. Of those, 2,682 were anterior circulation strokes. Of those, 373 received AISI. Stentrievers were used in 193 patients. Proximal occlusions (ICA terminus and MCA M1) were placed into Group A (n=150). Distal occlusions (MCA M2 and beyond) were placed into Group B (n=43). Group A had 6% SAH (n=9); Group B had 16% SAH (n=7) (p value <0.05). Conclusion: This study reveals an increased incidence of PT-SAH for distal LVOs. Main limitation of the study is the small sample size. Next generation stentrievers with smaller stent size and different design may decrease incidence of PT-SAH. Larger prospective RCTs are warranted to validate these results.

scholarly journals BIIB093 (intravenous glibenclamide) for the prevention of severe cerebral edema

2021 ◽  
Vol 12 ◽  
pp. 80
Author(s):  
Daniel W. Griepp ◽  
Jason Lee ◽  
Christina M. Moawad ◽  
Cyrus Davati ◽  
Juliana Runnels ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Cerebral Edema ◽  
Transient Receptor Potential ◽  
Small Sample Size ◽  
Vasogenic Edema ◽  
Receptor Potential ◽  
Outcome Data ◽  
Small Sample ◽  
Sulfonylurea Receptor

Background: Vasogenic edema in the setting of acute ischemic stroke can be attributed to the opening of transient receptor potential 4 channels, which are expressed in the setting of injury and regulated by sulfonylurea receptor 1 (SUR1) proteins. Glibenclamide, also known as glyburide, RP-1127, Cirara, and BIIB093, is a second-generation sulfonylurea that binds SUR1 at potassium channels and may significantly reduce cerebral edema following stroke, as evidenced by recent clinical trials. This review provides a comprehensive analysis of clinical considerations of glibenclamide use and current patient outcomes when administered in the setting of acute ischemic stroke to reduce severe edema. Methods: National databases (MEDLINE, EMBASE, Cochrane, and Google scholar databases) were searched to identify studies that reported on the clinical outcomes of glibenclamide administered immediately following acute ischemic stroke. Results: The pharmacological mechanism of glibenclamide was reviewed in depth as well as the known indications and contraindications to receiving treatment. Eight studies were identified as having meaningful clinical outcome data, finding statistically significant differences in glibenclamide treatment groups ranging from matrix metalloproteinase-9 serum levels, midline shift, modified Rankin Scores, National Institute of Health Stroke Score, and mortality endpoints. Conclusion: Studies analyzing the GAMES-Pilot and GAMES-PR trials suggest that glibenclamide has a moderate, however, measurable effect on intermediate biomarkers and clinical endpoints. Meaningful conclusions are limited by the small sample size of patients studied.

Sign in / Sign up

Export Citation Format

Share Document